The World Health Organization (WHO) has released recommendations on potential treatments and vaccines for the ongoing Ebola epidemic in the eastern Democratic Republic of Congo (DRC). During the WHO Director-General's visit to Bunia, the epicenter of the outbreak, the organization announced that several experimental drugs show promise for clinical trials. The recommended treatments include monoclonal antibodies MBP134 and Maftivimab, along with the antiviral remdesivir, with a combination therapy also suggested. For preventive measures, the oral antiviral obeldesivir may be administered to close contacts of confirmed cases. The rVSV Bundibugyo vaccine, developed by the International AIDS Vaccine Initiative, is viewed as the most promising but will not be ready for clinical trials for another 7-9 months. Alternatively, the ChAdOx1 Bundibugyo vaccine could be available in 2-3 months, pending further animal trial data. The WHO emphasizes the need for rigorous clinical trials and ongoing collaboration with local governments and health organizations to combat the epidemic effectively. As of the latest report, the DRC has recorded over 1,000 suspected cases of Ebola, resulting in 246 deaths.